Sygnature Discovery Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
1,000
- Latest Deal Type
-
Debt - Acquisition
- Financing Rounds
-
5
- Investments
-
10
Sygnature Discovery General Information
Description
Provider of integrated drug discovery resources and expertise intended to accelerate clients' research activities in creating better drugs for patients with unmet medical needs. The company offers intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimization and drug discovery programs with capabilities including medicinal chemistry, in vitro biology, computational chemistry and informatics and protein crystallography, assisting clients in drug discovery projects through pre-clinical candidates.
Contact Information
Website
www.sygnaturediscovery.comCorporate Office
- BioCity
- Pennyfoot Street
- Nottingham NG1 1GR
- England, United Kingdom
Corporate Office
- BioCity
- Pennyfoot Street
- Nottingham NG1 1GR
- England, United Kingdom
Sygnature Discovery Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sygnature Discovery Comparisons
Industry
Financing
Details
Sygnature Discovery Competitors (51)
One of Sygnature Discovery’s 51 competitors is BPS Bioscience, a Corporation company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BPS Bioscience | Corporation | San Diego, CA | ||||
| Domainex | Venture Capital-Backed | Saffron Walden, United Kingdom | ||||
| Verge Labs | Venture Capital-Backed | San Francisco, CA | ||||
| ABIONYX Pharma | Formerly VC-backed | Balma, France | ||||
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY |
Sygnature Discovery Patents
Sygnature Discovery Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260109692-A1 | Kcnt1 inhibitors and methods of use | Pending | 18-Oct-2024 | ||
| US-20260102383-A1 | Lpar1 inhibitors | Pending | 22-Apr-2024 | ||
| US-20250066394-A1 | 3-(2-(dimethylamino)ethyl)-1h-indol-4-yl derivatives | Pending | 25-Aug-2023 | ||
| US-20250066300-A1 | 3-(2-(dimethylamino)ethyl)-1h-indol-4-yl oligomeric derivatives | Pending | 25-Aug-2023 | ||
| US-20260109689-A1 | Novel compounds | Pending | 29-Jun-2023 | C07D405/14 |
Sygnature Discovery Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sygnature Discovery Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sygnature Discovery Investments (10)
Sygnature Discovery’s most recent deal was a Buyout/LBO with NuChem Sciences. The deal was made on 31-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NuChem Sciences | 31-Jul-2023 | Buyout/LBO | Drug Discovery | ||
| SB Drug Discovery | 17-Jan-2023 | Buyout/LBO | Drug Discovery | ||
| Peak Proteins | 12-Apr-2022 | Buyout/LBO | Other Pharmaceuticals and Biotechnology | ||
| XenoGesis | 24-Sep-2020 | Buyout/LBO | Other Pharmaceuticals and Biotechnology | ||
| Alderley Oncology | 03-Jun-2020 | Buyout/LBO | Laboratory Services (Healthcare) |
Sygnature Discovery Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Peak Proteins | Macclesfield, United Kingdom | 2014 | |
| NuChem Sciences | Saint-Laurent, Canada | 2011 | |
| XenoGesis | Nottingham, United Kingdom | 2011 | |
| RenaSci | Nottingham, United Kingdom | 2001 | |
| SB Drug Discovery | Glasgow, United Kingdom | 1994 |
Sygnature Discovery FAQs
-
When was Sygnature Discovery founded?
Sygnature Discovery was founded in 2004.
-
Where is Sygnature Discovery headquartered?
Sygnature Discovery is headquartered in Nottingham, United Kingdom.
-
What is the size of Sygnature Discovery?
Sygnature Discovery has 1,000 total employees.
-
What industry is Sygnature Discovery in?
Sygnature Discovery’s primary industry is Drug Discovery.
-
Is Sygnature Discovery a private or public company?
Sygnature Discovery is a Private company.
-
What is Sygnature Discovery’s current revenue?
The current revenue for Sygnature Discovery is .
-
Who are Sygnature Discovery’s investors?
Five Arrows, Torreal, N2 Business Growth Fund, and Pioneer Group have invested in Sygnature Discovery.
-
Who are Sygnature Discovery’s competitors?
BPS Bioscience, Domainex, Verge Labs, ABIONYX Pharma, and Attune Pharmaceuticals are some of the 51 competitors of Sygnature Discovery.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
